Berenberg has initiated coverage of BioNTech (BNTX) and Moderna (MRNA), citing their leadership positions in mRNA medicine.

Fintel reports that on November 18, 2024, HSBC upgraded their outlook for Moderna (NasdaqGS:MRNA) from Hold to Buy. Analyst ...

Leerink Partners analyst Mani Foroohar has reiterated their bearish stance on MRNA stock, giving a Sell rating on November 14.Don't Miss our ...

Berenberg analyst Harry Gillis initiated coverage of Moderna (MRNA) with a Hold rating and $42 price target. The firm says mRNA will ...

Turin Art week may be focused around Artissima, Italy’s oldest art fair, but there's must-see exhibitions to found across the ...

Bird flu has spread far and wide, infecting a range of species like chickens, skunks, cows, foxes and polar bears. But it's ...

Key Takeaways The S&P 500 added 0.4% on Tuesday, Nov. 19, as investors digested a strong report from a major retailer and ...

This Will Not End Well” is the incredible retrospective that the Neue Nationalgalerie dedicates to one of the most important ...

Lidia Fonseca, CIO of Pfizer, heads data solutions and products across Pfizer and spearheads digitizing processes such as drug discovery and clinical development. She also works to streamline digital ...

API technology startup Kong Inc. said today it has closed on a bumper $175 million late-stage round of funding, bringing its ...

Shares are trading lower in Europe after gaining in Asia after U.S. stocks recovered somewhat from last week's swoon. Oil ...

Investors have been bracing for some potential downsides of Trump’s reshaping of the economy. Moderna rose 7.2% on Monday but ...